Do you have the same question? Follow this Question
Apr 22, 2026 - 02:15 PM
We’ve provided several answers to questions related to Ingrezza (Valbenazine) , see some other helpful Q&A related to this product.
Question: Does this medication have a boxed warning?
Answer: Yes, it carries a US FDA boxed warning for increased risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. The boxed warning highlights the importance of monitoring mood and behavior changes during treatment.
Question: What are the main side effects in patients with tardive dyskinesia?
Answer: Excessive sleepiness is the most common side effect for patients with tardive dyskinesia. Recognizing this helps patients and caregivers monitor for drowsiness and adjust activities as needed.
Question: What are the brand names for this medication?
Answer: The brand name is Ingrezza. Brand names help patients and healthcare providers easily identify and distinguish medications.
Question: What inactive ingredients are in the capsules?
Answer: The capsules contain hypromellose, isomalt, magnesium stearate, pregelatinized starch, and silicified microcrystalline cellulose. The capsule shells contain candurin silver fine, FD&C Blue #1, FD&C Red #40, and gelatin. Inactive ingredients play roles in capsule stability, appearance, and absorption.
Question: What is the route of administration for this medication?
Answer: The route of administration is oral. Oral administration is convenient and generally well-accepted by patients, supporting adherence to treatment.
Question: What is the recommended storage temperature for the capsules?
Answer: The capsules should be stored between 15°C and 30°C (59°F and 86°F). Proper storage maintains the medication’s effectiveness and safety.
Question: What is the elimination half-life of the active ingredient?
Answer: The elimination half-life ranges from 15 to 22 hours. The half-life indicates how long the medication stays active in the body, which influences dosing schedules and frequency.
Question: What is the legal status of this medication?
Answer: This medication is available by prescription only. Prescription-only status ensures that a healthcare professional evaluates the patient's suitability for the medication, promoting safe use.
Question: Are there different forms of this medication for oral use?
Answer: Yes, it is available as standard capsules and as Sprinkle capsules for oral administration. The Sprinkle capsules offer an alternative for patients who may have difficulty swallowing whole capsules, enhancing medication adherence.
Question: Does valbenazine increase dopamine?
Answer: Valbenazine does not directly increase dopamine levels. Instead, it works by inhibiting the vesicular monoamine transporter 2 (VMAT2), which reduces the release of dopamine into synapses. This helps to decrease excessive dopamine activity associated with conditions like tardive dyskinesia.
Question: What is the black box warning for INGREZZA?
Answer: INGREZZA (valbenazine) does not have a black box warning. A black box warning is the most serious warning required by the FDA for prescription drugs, and INGREZZA’s prescribing information does not include one.
